Liver Cancer

Cabometyx™ May Be ‘New Treatment Option’ for Liver Cancer (02-20-2018)

CancerConnect News:  Treatment with Cabometyx  (cabozantinib) significantly improved outcomes in patients with advanced hepatocellular carcinoma (HCC), leading researchers to suggest that it could offer a new treatment option for this patient population. ... Continue Reading

Keytruda Immunotherapy Appears Active for Treatment of Liver Cancer (02-15-2018)

CancerConnect News:  According to the results of a study presented at the recent gastrointestinal cancer symposia, Keytruda (pembrolizumab) is an active treatment for advanced liver cancer in patients who have already been treated with Nexavar (sorafenib).1 About... Continue Reading

Opdivo Precision Cancer Medicine Improves Outcomes in Advanced Liver Cancer (05-18-2017)

Results from the CheckMate 040 clinical trial have been recently reported and found that Opdivo (nivolumab), an immuno-oncology drug which acts by modulating the immune system, produces durable responses with long-term survival rates in patients with... Continue Reading

First New Drug for Liver Cancer in a Decade: Stivarga (05-8-2017)

The US Food and Drug Administration (FDA) has expanded the indication for Stivarga (regorafenib) to now include treatment for patients with hepatocellular carcinoma (HCC) who have previously been treated with the drug Nexavar. Expansion of Stivarga, ‘s... Continue Reading

February: Gallbladder and Bile Duct Awareness Month (02-18-2016)

Located underneath the liver, the gallbladder is responsible for the concentration and storage of bile which helps to digest the fats in food as they pass through the intestines. Bile is either released from the liver directly into ducts that carry it... Continue Reading

Vistogard® Approved for Life-Threatening Toxicities of Certain Chemotherapy Agents (02-11-2016)

The United States Food and Drug Administration (FDA) approved Vistogard (uridine triacetate) for the treatment of life-threatening toxicities caused by the chemotherapy drugs fluorouracil or capecitabine. The approved indication is for the “emergency... Continue Reading

Infection with Hepatitis C Increases Risk of Cirrhosis (03-10-2015)

People who are infected with the hepatitis C virus (HCV) have a higher risk for developing the liver disease cirrhosis, particularly within the first five years after infection. These findings were released in JAMA Internal Medicine. Cirrhosis, or late-stage... Continue Reading

Hepatitis C Cases Could Be Cured By Novel Oral Drug Regimen (07-31-2014)

According to the results of two new clinical studies published in The Lancet, two new pill-only antiviral drug regimens for hepatitis C virus infection provide shorter and more effective treatment options with fewer side effects for most patients affected... Continue Reading

Liver Cancer Drug Livatag® Granted U.S. Food and Drug Administration Fast Track Designation (05-27-2014)

The drug Livatag® (doxorubicin Transdrug™) has received fast-track designation from the U.S. Food and Drug Administration (FDA) for the treatment of primary liver cancer after treatment with Nexavar® (sorafenib). This was recently announced in a press... Continue Reading

Coffee Cuts Risk of Liver Cancer (11-8-2013)

Good news for coffee addicts—new research has found that regular coffee consumption can reduce the risk of liver cancer by 40 percent. In fact, the study—published in Clinical Gastroenterology and Hepatology—found that people who consume more than... Continue Reading

Next Page »